BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 17067916)

  • 1. Albendazole for mass drug administration to eliminate lymphatic filariasis.
    Sabesan S
    Lancet Infect Dis; 2006 Nov; 6(11):684-5. PubMed ID: 17067916
    [No Abstract]   [Full Text] [Related]  

  • 2. Potential Value of Triple Drug Therapy with Ivermectin, Diethylcarbamazine, and Albendazole (IDA) to Accelerate Elimination of Lymphatic Filariasis and Onchocerciasis in Africa.
    Fischer PU; King CL; Jacobson JA; Weil GJ
    PLoS Negl Trop Dis; 2017 Jan; 11(1):e0005163. PubMed ID: 28056015
    [No Abstract]   [Full Text] [Related]  

  • 3. Improving community participation to eliminate lymphatic filariasis in American Samoa.
    King JD; Zielinski-Gutierrez E; Pa'au M; Lammie P
    Acta Trop; 2011 Sep; 120 Suppl 1():S48-54. PubMed ID: 20932818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coverage survey for assessing mass drug administration against lymphatic filariasis in Gulbarga district, Karnataka, India.
    Ranganath BG
    J Vector Borne Dis; 2010 Mar; 47(1):61-4. PubMed ID: 20231778
    [No Abstract]   [Full Text] [Related]  

  • 5. Global programme to eliminate lymphatic filariasis.
    World Health Organization
    Wkly Epidemiol Rec; 2005 Jun; 80(23):202-12. PubMed ID: 16033148
    [No Abstract]   [Full Text] [Related]  

  • 6. Evidence for the use of albendazole for the elimination of lymphatic filariasis.
    Sunish IP; Rajendran R; Mani TR; Dash AP; Tyagi BK
    Lancet Infect Dis; 2006 Mar; 6(3):125-6. PubMed ID: 16500593
    [No Abstract]   [Full Text] [Related]  

  • 7. Community-wide reduction in prevalence and intensity of intestinal helminths as a collateral benefit of lymphatic filariasis elimination programs.
    De Rochars MB; Direny AN; Roberts JM; Addiss DG; Radday J; Beach MJ; Streit TG; Dardith D; Lafontant JG; Lammie PJ
    Am J Trop Med Hyg; 2004 Oct; 71(4):466-70. PubMed ID: 15516644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toward the elimination of lymphatic filariasis by 2020: treatment update and impact assessment for the endgame.
    Rebollo MP; Bockarie MJ
    Expert Rev Anti Infect Ther; 2013 Jul; 11(7):723-31. PubMed ID: 23879610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mass drug administration to treat lymphatic filariasis.
    Ravindran B
    Lancet; 2002 Jun; 359(9321):1948. PubMed ID: 12057582
    [No Abstract]   [Full Text] [Related]  

  • 10. Is anthelmintic resistance a threat to the program to eliminate lymphatic filariasis?
    McCarthy J
    Am J Trop Med Hyg; 2005 Aug; 73(2):232-3. PubMed ID: 16103580
    [No Abstract]   [Full Text] [Related]  

  • 11. Model-based analysis of trial data: microfilaria and worm-productivity loss after diethylcarbamazine-albendazole or ivermectin-albendazole combination therapy against Wuchereria bancrofti.
    de Kraker ME; Stolk WA; van Oortmarssen GJ; Habbema JD
    Trop Med Int Health; 2006 May; 11(5):718-28. PubMed ID: 16640625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Report on the mid-term assessment of microfilaraemia reduction in sentinel sites of 13 countries of the Global Programme to Eliminate Lymphatic Filariasis.
    Wkly Epidemiol Rec; 2004 Oct; 79(40):358-65. PubMed ID: 15631012
    [No Abstract]   [Full Text] [Related]  

  • 13. Targeting of children in filariasis mass drug administration.
    Rajendran R; Sunish IP; Mani TR; Munirathinam A; Satyanarayana K
    Lancet; 2002 Nov; 360(9343):1430. PubMed ID: 12424026
    [No Abstract]   [Full Text] [Related]  

  • 14. Global programme to eliminate lymphatic filariasis: progress report, 2016.
    Wkly Epidemiol Rec; 2017 Oct; 92(40):594-607. PubMed ID: 28984121
    [No Abstract]   [Full Text] [Related]  

  • 15. Community empowerment in the control of lymphatic filariasis in Misima, Milne Bay Province using diethylcarbamazine in combination with albendazole.
    Selve BP; Bwadua S; Misa M; James K; Usurup JP; Turner P; Melrose W; Yad W; Samuel R; Eddie C
    P N G Med J; 2000; 43(3-4):183-7. PubMed ID: 11939299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of repeated rounds of mass drug administration with diethylcarbamazine plus albendazole on bancroftian filariasis in Papua New Guinea.
    Weil GJ; Kastens W; Susapu M; Laney SJ; Williams SA; King CL; Kazura JW; Bockarie MJ
    PLoS Negl Trop Dis; 2008; 2(12):e344. PubMed ID: 19065257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lymphatic filariasis elimination programme in India: progress and challenges.
    Ramaiah KD
    Trends Parasitol; 2009 Jan; 25(1):7-8. PubMed ID: 19008150
    [No Abstract]   [Full Text] [Related]  

  • 18. Endpoints for lymphatic filariasis programs.
    Grady CA; de Rochars MB; Direny AN; Orelus JN; Wendt J; Radday J; Mathieu E; Roberts JM; Streit TG; Addiss DG; Lammie PJ
    Emerg Infect Dis; 2007 Apr; 13(4):608-10. PubMed ID: 17553278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Residual microfilaraemia in rural pockets of South India after five rounds of DEC plus albendazole administration as part of the LF elimination campaign.
    Kalimuthu M; Sunish IP; Nagaraj J; Munirathinam A; Kumar VA; Arunachalam N; White GB; Tyagi BK
    J Vector Borne Dis; 2015 Jun; 52(2):182-4. PubMed ID: 26119554
    [No Abstract]   [Full Text] [Related]  

  • 20. Effectiveness of two annual, single-dose mass drug administrations of diethylcarbamazine alone or in combination with albendazole on soil-transmitted helminthiasis in filariasis elimination programme.
    Mani TR; Rajendran R; Sunish IP; Munirathinam A; Arunachalam N; Satyanarayana K; Dash AP
    Trop Med Int Health; 2004 Sep; 9(9):1030-5. PubMed ID: 15361118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.